BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
NCT07622810 on ClinicalTrials.gov · last registry update 2026-06-03
Registered but not yet open, with 352 participants planned. Due to report December 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Percent Change in Body Weight From Baseline to Week 36. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Carnot Laboratories
- Sponsor type
- Industry
- Enrollment
- 352
- Started
- 2026-09
- Primary completion
- 2027-12 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent Change in Body Weight From Baseline to Week 36
Conditions studied
Obesity & Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.